Newsmakers

Hoth Therapeutics (NASDAQ: HOTH) Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

Collaborative program with the U.S. Department of Veterans Affairs aims to validate GDNF as a first-in-class biologic for obesity and hepatic health. NEW YORK, Oct. 27, 2025  — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on […]

Newsmakers

Hoth Therapeutics (NASDAQ: HOTH) Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

>80% KIT knock-down and significant tumor-volume reduction in systemic mastocytosis and GIST models; GLP-validated bio analytics complete; Japan Patent protects through 2039 as IND work advances. Planned Next Steps (Near-Term): Complete GLP toxicology and CMC packages; submit […]

Uncategorized

Worksport (NASDAQ: WKSP) Reports Record Q3 Revenue Growth and 2,300 Basis-Point Margin Expansion Ahead of Three Clean-Energy Product Launches

Margins surpassing 31%, along with 62% year-over-year topline growth to a $5MM quarter, underscore accelerating U.S. manufacturing scale and profitability before the commercialization of the next line of products: SOLIS™, COR™, and Aetherlux™ by Terravis. West Seneca, New York, Oct. 16, 2025  — Worksport Ltd. […]

Newsmakers

Worksport Ltd. (NASDAQ: WKSP) Successfully Closes $10 Million Regulation A Funding; Launch-Ready and Fully Capitalized for Early 2026 Cash Flow Positivity

Offering complete with capital overhang removed; $4.50 warrants provide future success-based capital as Worksport targets Q4 flagship launches and growth execution. West Seneca, New York, Oct. 15, 2025 — Worksport Ltd. (NASDAQ: WKSP) (“Worksport” or […]

Newsmakers

Hoth Therapeutics (NASDAQ: HOTH) Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Under the new entitlement agreement, Hoth Therapeutics secures annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research NEW YORK, Oct. 8, 2025  […]

Newsmakers

Hoth Therapeutics (NASDAQ: HOTH) CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

Presentation to highlight advancements in Hoth’s clinical pipeline, including HT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology program targeting KIT-driven tumors NEW YORK, Oct. 7, 2025  — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company […]

Newsmakers

Snow Lake (NASDAQ: LITM) to Acquire Global Uranium and Enrichment Limited Creating a U.S. Focused Nuclear Fuel Cycle Company

Winnipeg, Manitoba– October 6, 2025 – Snow Lake Resources Ltd., d/b/a Snow Lake Energy (NASDAQ: LITM) (Snow Lake), a uranium exploration and development company, is pleased to announce that it has entered into a definitive […]

Newsmakers

Worksport (NASDAQ: WKSP) Subsidiary Terravis Energy Selected for Competitive NTAP Award to Analyze ZeroFrost Heat Pump Technology in Alaska

Federal Collaboration Marks Major Milestone as Worksport Targets Multi-Billion-Dollar Heat Pump Market West Seneca, New York–October 6, 2025 – Worksport Ltd. (NASDAQ: WKSP) (“Worksport” or the “Company”), through its subsidiary Terravis Energy, today announced a […]

Newsmakers

Wellgistics Health (NASDAQ:WGRX) and TheracosBio Partner to Expand Nationwide, PBM-Free Access to Brenzavvy(R), an FDA-Approved Diabetes Therapy, Through 6,500+ Pharmacies

TAMPA, FL  / September 30, 2025 / Wellgistics Health, Inc. (“Wellgistics Health” or the “Company”) (NASDAQ:WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced a strategic collaboration with TheracosBio, […]

Newsmakers

Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001 aims to address these […]